Technological projects portfolio

Enterococci, and in particular vancomycin-resistant enterococci (VRE) are responsible for opportunistic infections. They take advantage of an imbalance in the intestinal microbiota, known as dysbiosis, to proliferate and infect predisposed or elderly patients or those with immunodeficiencies.

The search for preventive strategies to combat these multiresistant pathogens is an urgent priority of the WHO

The COOPERATE Project aims to develop a bacteriotherapy strategy from a mixture of strains of commensal bacteria naturally present in the intestinal tract. Identified by mathematical modelling and associated with better elimination of VRE, they produced a protective barrier in preclinical trials.

This technology will enable recolonization of the microbiota of patients suffering from dysbiosis, which will prevent the proliferation of, and infection by, multiresistant VRE.

The target population of the COOPERATE Project are patients at risk: immunosuppressed patients, VRE carriers, transplant patients or dialysis patients for whom it is necessary to restore the barrier effect of the microbiota after dysbiosis.

This strategy of identifying strains of interest and preventing infection by pathogens could be extended to other bacteriotherapy applications in association with antibiotics, use of which must be reduced.